Securities analysts have cut their earnings estimates...

Securities analysts have cut their earnings estimates for Genentech Inc. amid worries that sales of the heart medicine TPA may not be as strong as expected. “Sales of the drug in the fourth quarter far exceeded expectations, but first-quarter shipments were less than expected,” said Linda Miller, an analyst with Paine Webber. Miller has cut her earnings estimates for the year to $1.25 a share from $1.50. Genentech began selling TPA last November. Analyst Denise Gilbert of Montgomery Securities said she cut her earnings estimates for South San Francisco-based Genentech to $1.25 a share from $1.39.